Type I interferon mimetics bypass vaccinia virus decoy receptor virulence factor for protection of mice against lethal infection
Clinical and Vaccine Immunology, ISSN: 1556-679X, Vol: 21, Issue: 8, Page: 1178-1184
2014
- 6Citations
- 10Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations6
- Citation Indexes6
- CrossRef6
- Captures10
- Readers10
- 10
Article Description
The canonical model of interferon (IFN) signaling focuses solely on the activation of STAT transcription factors which, according to the model, are initiated by the singular event of cross-linkage of the receptor extracellular domain by the IFN. The IFN has no further function beyond this. The model thus provides no approach to circumventing poxviruses decoy receptors that compete with the IFN receptors for IFNs. This simple event has allowed smallpox virus to decimate human populations throughout the ages. We have developed a noncanonical model of IFN signaling that has resulted in the development of small peptide mimetics to both types I and II IFNs. In this report, we focus on a type I IFN mimetic at positions 152 to 189, IFN-α1(152-189), which corresponds to the C terminus of human IFN-α1. This mimetic functions intracellularly and is thus not recognized by the B18R vaccinia virus decoy receptor. Mimetic synthesized with an attached palmitate (lipo-) for cell penetration protects mice from a lethal dose of vaccinia virus, while the parent IFN-α1 is ineffective. Unlike IFN-α1, the mimetic does not bind to the B18R decoy receptor. It further differs from the parent IFN in that it lacks the toxicity of weight loss and bone marrow suppression in mice while at the same time possessing a strong adjuvant effect on the immune system. The mimetic is thus an innate and adaptive immune regulator that is evidence of the dynamic nature of the noncanonical model of IFN signaling, in stark contrast to the canonical or classical model of signaling. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84906672147&origin=inward; http://dx.doi.org/10.1128/cvi.00204-14; http://www.ncbi.nlm.nih.gov/pubmed/24964806; https://journals.asm.org/doi/10.1128/CVI.00204-14; http://cvi.asm.org/lookup/doi/10.1128/CVI.00204-14; https://syndication.highwire.org/content/doi/10.1128/CVI.00204-14; https://dx.doi.org/10.1128/cvi.00204-14; https://cvi.asm.org/content/21/8/1178; https://cvi.asm.org/content/21/8/1178.abstract; https://cvi.asm.org/content/21/8/1178.full.pdf; https://journals.asm.org/doi/abs/10.1128/CVI.00204-14; http://cdli.asm.org/cgi/doi/10.1128/CVI.00204-14; https://journals.asm.org/journal/cvi; http://cvi.asm.org/content/21/8/1178; https://cvi.asm.org/content/cdli/21/8/1178.full.pdf; http://cvi.asm.org/cgi/doi/10.1128/CVI.00204-14
American Society for Microbiology
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know